155 related articles for article (PubMed ID: 11694847)
1. Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C.
Dumoulin FL; Wennrich U; Nischalke HD; Leifeld L; Fischer HP; Sauerbruch T; Spengler U
J Hum Virol; 2001; 4(4):195-9. PubMed ID: 11694847
[TBL] [Abstract][Full Text] [Related]
2. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI; Lagging M; Westin J; Dhillon AP; Dustin LB; Pawlotsky JM; Neumann AU; Ferrari C; Missale G; Haagmans BL; Schalm SW; Zeuzem S; Negro F; Verheij-Hart E; Hellstrand K;
J Infect Dis; 2006 Oct; 194(7):895-903. PubMed ID: 16960776
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
Di Bisceglie AM; Fan X; Chambers T; Strinko J
J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of Toll-like receptors 7 & 8 mRNA in monocytes of patients with chronic hepatitis C infection: correlation with interferon and ribavirin treatment.
Boghdadi G; Seleem WM
Egypt J Immunol; 2014; 21(1):67-75. PubMed ID: 25204046
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
Pham TN; Lin DM; Mulrooney-Cousins PM; Churchill ND; Kowala-Piaskowska A; Mozer-Lisewska I; Machaj A; Pazgan-Simon M; Zalewska M; Simon K; King D; Reddy SB; Michalak TI
J Med Virol; 2013 Mar; 85(3):441-8. PubMed ID: 23280583
[TBL] [Abstract][Full Text] [Related]
6. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.
Trimoulet P; de Lédinghen V; Foucher J; Castéra L; Fleury H; Couzigou P
J Med Virol; 2004 Jan; 72(1):46-51. PubMed ID: 14635010
[TBL] [Abstract][Full Text] [Related]
8. Changes in TNF-alpha mRNA levels in the peripheral blood of patients with chronic hepatitis C virus (HCV) infection during alpha-interferon and ribavirin therapy.
Sypniewski D; Jurzak M; Cholewa K; Gola J; Mazurek U; Wilczok T; Rozek-Kostórkiewicz J; Mazur W; Gonciarz Z
Viral Immunol; 2004; 17(4):580-7. PubMed ID: 15671755
[TBL] [Abstract][Full Text] [Related]
9. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
10. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
[TBL] [Abstract][Full Text] [Related]
11. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
12. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
14. Hepatic metallothionein in patients with chronic hepatitis C: relationship with severity of liver disease and response to treatment.
Carrera G; Paternain JL; Carrere N; Folch J; Courtade-Saïdi M; Orfila C; Vinel JP; Alric L; Pipy B
Am J Gastroenterol; 2003 May; 98(5):1142-9. PubMed ID: 12809840
[TBL] [Abstract][Full Text] [Related]
15. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads.
Enomoto M; Nishiguchi S; Kohmoto M; Tamori A; Habu D; Takeda T; Seki S; Shiomi S
J Viral Hepat; 2004 Sep; 11(5):448-54. PubMed ID: 15357651
[TBL] [Abstract][Full Text] [Related]
16. Hepatic interferon receptor mRNA expression: clinical relevance and its relationship with effectiveness of interferon plus ribavirin therapy in patients with genotype 1b hepatitis C virus infection.
Lee CM; Kee KM; Hung CH; Eng HL; Chang CH; Huang CM; Wang JH; Hu TH; Lu SN; Changchien CS; Chen WJ
Antivir Ther; 2006; 11(1):17-23. PubMed ID: 16518956
[TBL] [Abstract][Full Text] [Related]
17. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
18. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
[TBL] [Abstract][Full Text] [Related]
19. Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
Gerner P; Hilbich J; Wenzl TG; Behrens R; Walther F; Kliemann G; Enninger A; Wirth S
J Pediatr Gastroenterol Nutr; 2010 Aug; 51(2):187-90. PubMed ID: 20512050
[TBL] [Abstract][Full Text] [Related]
20. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
